<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01704794</url>
  </required_header>
  <id_info>
    <org_study_id>LASUTH/SCD01/2012</org_study_id>
    <nct_id>NCT01704794</nct_id>
  </id_info>
  <brief_title>Quality of Life Study for Sickle Cell Patients Treated With Jobelyn (Sorghum Bicolor Extract)</brief_title>
  <official_title>Antioxidant Effect of the Extract of Jobelyn (Sorghum Bicolor) on the Quality of Life of Patients With Sickle Cell Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lagos State University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lagos State University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the antioxidant effect of prolonged use of sorghum
      bicolor (jobelyn) to increase the level of plasma superoxide dismutase and glutathione
      reductase in patients with sickle cell disease and to determine if there is any improvement
      in the quality of life of the patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Jobelyn is an extract of sorghum bicolor that is popular in Nigeria as a herbal food
      supplement. This extract has been shown to have a high oxygen radical absorbance capacity
      (ORAC 37,622micro mole TE/g) compared to other botanical preparations 1. A second proven
      property is its anti inflammatory effect with a selective COX 2 inhibition 2. It has also
      been shown to correct anaemia induced in experimental rabbit by trypanosome brucei brucei 3.

      Jobelyn is being consumed as a herbal nutritional supplement in many disorders including
      sickle cell disease in Nigeria without complaint in over 15 years. The toxicology profile is
      impressive with a wide therapeutic range.

      Nigeria is one of the countries with the largest burden of sickle cell disease. It is a
      chronic genetic disorder that accounts for absenteeism at school and at work place. There is
      also a significant shortening of the life span of the affected patients. Sickle cell anaemia
      presents with recurrent bone pains and progressive organ damage that affects negatively the
      quality of life of the patients. Available measures that have been in use include use of
      hydroxyurea, chronic and acute red cell transfusion and haematopoietic stem cell
      transplantation. These have limitations in terms of adverse effects, cost and availability.

      The pathogenesis involves intracellular precipitation of the mutant haemoglobin, rigidity of
      the cell, adhesion of cells to the endothelium. These cause recurrent tissue hypoxia and
      reperfusion which cause release of reactive oxygen series and agents of inflammation. The
      extract of sorghum is therefore expected to improve the quality of life of these patients.

      Previous work done, have not investigated the long time effect of the extract on the quality
      of life of sickle cell patients. This study is therefore designed to compare the quality of
      life of patients on 500mg daily, 250mg daily and 2mg daily of jobelyn using adjusted standard
      tools. The secondary outcomes to study are changes in indicators of inflammation and systemic
      antioxidants in these patients. The study period is 12 months so that the period shall
      involve all the weather conditions in the region.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">September 2014</completion_date>
  <primary_completion_date type="Anticipated">April 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>number of severe bone pain crises and hospital admissions in one year</measure>
    <time_frame>12 months</time_frame>
    <description>Use of health related quality of life measures tool SF-36 and self reporting questionnaires</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Antioxidant and anti-inflammatory effect</measure>
    <time_frame>12 months</time_frame>
    <description>Increase in glutathion reductase, Increase in superoxide dismutase, Reduction in C reactive protein, Reduction in lactate dehydrogenase and Liver enzymes tests</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">96</enrollment>
  <condition>Other Sickle-cell Disorders With Crisis, Unspecified</condition>
  <arm_group>
    <arm_group_label>Folic Acid + Paludrine +Jobelyn (500mg)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Folic acid 5mg given twice daily. Paludrine 50mg to 20mg daily. Jobelyn 500mg once daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Folic Acid + Paludrine +Jobelyn (250mg.)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Folic Acid 5mg daily Paludrine 20 - 40mg daily Jobelyn 250mg daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Folic Acid + Paludrine + Jobelyn (2mg)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Folic Acid 5mg daily Paludrine 20 - 40mg daily Jobelyn 2mg daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Folic Acid + Paludrine + Jobelyn (500mg)</intervention_name>
    <description>Combination of routine drugs + Jobelyn</description>
    <arm_group_label>Folic Acid + Paludrine +Jobelyn (500mg)</arm_group_label>
    <other_name>Routine drugs</other_name>
    <other_name>Sorghum bicolor extract (Jobelyn 500mg)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Folic Acid + Paludrine + Jobelyn (250mg)</intervention_name>
    <description>Standard routine drugs for treatment of SCD with 250mg Jobelyn</description>
    <arm_group_label>Folic Acid + Paludrine +Jobelyn (250mg.)</arm_group_label>
    <other_name>Routine drugs</other_name>
    <other_name>Sorghum bicolor extract (250mg)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Folic Acid + Paludrine + Jobelyn (2mg)</intervention_name>
    <description>Combination of Paludrine + Folic Acid and Jobelyn 2mg (Sorghum bicolor extract)</description>
    <arm_group_label>Folic Acid + Paludrine + Jobelyn (2mg)</arm_group_label>
    <other_name>Other Names: Routine drugs</other_name>
    <other_name>Jobelyn (Sorghum bicolor extract)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. AGE : 14 To 40 years

          2. SEX: Both sexes

          3. Homozygous for the S gene (SS)

        Exclusion Criteria:

          1. Age below 14 years and above 40 years

          2. Evidence of organ failure i.e heart failure, renal failure

          3. No consent for study

          4. Poor adherence to treatment and irregular visit to the clinic

          5. Presence of chronic inflammation

          6. Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>A O Dosunmu, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lagos State University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>A O Dosunmu, M.D.</last_name>
    <phone>2348023369785</phone>
    <email>doyin_dosunmu@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Lagos State University Teaching Hospital</name>
      <address>
        <city>Ikeja</city>
        <state>Lagos</state>
        <zip>100001</zip>
        <country>Nigeria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>A O Dosunmu, M.D.</last_name>
      <phone>2348023369785</phone>
      <email>doyin_dosunmu@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>A O Dosunmu, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>O O Odusanya, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>I N AKinwunmi, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>A A Akinbami, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>M O Dada, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>T M Balogun, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>C K Yemitan, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>J A Onakoya, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>U O Oyekan, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Nigeria</country>
  </location_countries>
  <reference>
    <citation>Bröhan M, Jerkovic V, Collin S. Potentiality of red sorghum for producing stilbenoid-enriched beers with high antioxidant activity. J Agric Food Chem. 2011 Apr 27;59(8):4088-94. doi: 10.1021/jf1047755. Epub 2011 Mar 7.</citation>
    <PMID>21381750</PMID>
  </reference>
  <reference>
    <citation>Geera B, Ojwang LO, Awika JM. New highly stable dimeric 3-deoxyanthocyanidin pigments from sorghum bicolor leaf sheath. J Food Sci. 2012 May;77(5):C566-72. doi: 10.1111/j.1750-3841.2012.02668.x. Epub 2012 Apr 10.</citation>
    <PMID>22489620</PMID>
  </reference>
  <reference>
    <citation>Kayodé AP, Nout MJ, Linnemann AR, Hounhouigan JD, Berghofer E, Siebenhandl-Ehn S. Uncommonly high levels of 3-deoxyanthocyanidins and antioxidant capacity in the leaf sheaths of dye sorghum. J Agric Food Chem. 2011 Feb 23;59(4):1178-84. doi: 10.1021/jf103963t. Epub 2011 Jan 25.</citation>
    <PMID>21322653</PMID>
  </reference>
  <reference>
    <citation>Yang L, Browning JD, Awika JM. Sorghum 3-deoxyanthocyanins possess strong phase II enzyme inducer activity and cancer cell growth inhibition properties. J Agric Food Chem. 2009 Mar 11;57(5):1797-804. doi: 10.1021/jf8035066.</citation>
    <PMID>19256554</PMID>
  </reference>
  <reference>
    <citation>Shih CH, Siu SO, Ng R, Wong E, Chiu LC, Chu IK, Lo C. Quantitative analysis of anticancer 3-deoxyanthocyanidins in infected sorghum seedlings. J Agric Food Chem. 2007 Jan 24;55(2):254-9.</citation>
    <PMID>17227050</PMID>
  </reference>
  <reference>
    <citation>Hunt DM, Emerson SU, Wagner RR. RNA- temperature-sensitive mutants of vesicular stomatitis virus: L-protein thermosensitivity accounts for transcriptase restriction of group I mutants. J Virol. 1976 May;18(2):596-603.</citation>
    <PMID>178900</PMID>
  </reference>
  <reference>
    <citation>Burdette A, Garner PL, Mayer EP, Hargrove JL, Hartle DK, Greenspan P. Anti-inflammatory activity of select sorghum (Sorghum bicolor) brans. J Med Food. 2010 Aug;13(4):879-87. doi: 10.1089/jmf.2009.0147.</citation>
    <PMID>20673059</PMID>
  </reference>
  <reference>
    <citation>Park JH, Darvin P, Lim EJ, Joung YH, Hong DY, Park EU, Park SH, Choi SK, Moon ES, Cho BW, Park KD, Lee HK, Kim MJ, Park DS, Chung IM, Yang YM. Hwanggeumchal sorghum induces cell cycle arrest, and suppresses tumor growth and metastasis through Jak2/STAT pathways in breast cancer xenografts. PLoS One. 2012;7(7):e40531. doi: 10.1371/journal.pone.0040531. Epub 2012 Jul 6.</citation>
    <PMID>22792362</PMID>
  </reference>
  <reference>
    <citation>Wu L, Huang Z, Qin P, Yao Y, Meng X, Zou J, Zhu K, Ren G. Chemical characterization of a procyanidin-rich extract from sorghum bran and its effect on oxidative stress and tumor inhibition in vivo. J Agric Food Chem. 2011 Aug 24;59(16):8609-15. doi: 10.1021/jf2015528. Epub 2011 Jul 29.</citation>
    <PMID>21780844</PMID>
  </reference>
  <reference>
    <citation>Awika JM, McDonough CM, Rooney LW. Decorticating sorghum to concentrate healthy phytochemicals. J Agric Food Chem. 2005 Aug 10;53(16):6230-4.</citation>
    <PMID>16076098</PMID>
  </reference>
  <reference>
    <citation>Gee L, Abbott J, Conway SP, Etherington C, Webb AK. Validation of the SF-36 for the assessment of quality of life in adolescents and adults with cystic fibrosis. J Cyst Fibros. 2002 Sep;1(3):137-45.</citation>
    <PMID>15463820</PMID>
  </reference>
  <reference>
    <citation>Okochi,V.I.,Okpuzor J, Okubena M.O., Awoyemi A.K. 2003 . The Influence of African Herbal Formula on the haematological parameters of trypanosome infected rats. African Journal of Biotechnology. 2 (9), 312-316.</citation>
  </reference>
  <reference>
    <citation>Erah P,O., Asonye C.C. Okhamafe A.O. 2003. Response of trypanosome brucei brucei induced anaemiato a commercialherbal preparation. African Journal of Biotechnology. 2,9, 307-311.</citation>
  </reference>
  <reference>
    <citation>Ogwumike OO. Hemopoietic effect of aqueous extract of the leaf sheath of Sorghum bicolor in albino rats. African Journal of Biomedical. Research. (2002): Vol 5; 69 - 71</citation>
  </reference>
  <reference>
    <citation>Oladiji AT, Jacob TO, Yakubu MT. Anti-anaemic potentials of aqueous extract of Sorghum bicolor (L.) moench stem bark in rats. J Ethnopharmacol. 2007 May 22;111(3):651-6. Epub 2007 Jan 18.</citation>
    <PMID>17306481</PMID>
  </reference>
  <reference>
    <citation>Akande IS, Oseni AA, Biobaku OA. Effects of aqueous extract of Sorghum bicolor on hepatic, histological and haematological indices in rats. Journal of Cell and Animal Biology 4(9), 137-142, 2010.</citation>
  </reference>
  <reference>
    <citation>Nwinyi FC, Kwanashie HO. Evaluation of aqueous methanolic extract of Sorghum bicolor leaf base for antinociceptive and anti-inflammatory activities. African Journal of Biotechnology, 8 (18), 4642-4649, 2009.</citation>
  </reference>
  <reference>
    <citation>Eniojukan JF, Bolajoko AA. Toxicological Profiles of Commercial Herbal Preperation, Jobelyn. International Journal of Health Research, 2(4), 369-374, 2009.</citation>
  </reference>
  <reference>
    <citation>USDA Database for the Oxygen Radical Absorbance Capacity (ORAC) of Selected Foods, Release 2, U.S. Department of Agriculture, 2010.</citation>
  </reference>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 3, 2012</study_first_submitted>
  <study_first_submitted_qc>October 10, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 11, 2012</study_first_posted>
  <last_update_submitted>April 1, 2013</last_update_submitted>
  <last_update_submitted_qc>April 1, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 4, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Lagos State University</investigator_affiliation>
    <investigator_full_name>Dr. A. O. Dosunmu</investigator_full_name>
    <investigator_title>CONSULTANT IN THE DEPARTMENT OF HAEMATOLOGY &amp; BLOOD TRANSFUSION, LASUTH</investigator_title>
  </responsible_party>
  <keyword>Sickle Cell Anemia</keyword>
  <keyword>Quality of Life</keyword>
  <keyword>Antioxidant</keyword>
  <keyword>Anti inflammatory</keyword>
  <keyword>Sorghum bicolor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Sickle Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Folic Acid</mesh_term>
    <mesh_term>Vitamin B Complex</mesh_term>
    <mesh_term>Antioxidants</mesh_term>
    <mesh_term>Proguanil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

